X4 Pharmaceuticals Inc (NASDAQ: XFOR) kicked off on Monday, down -5.44% from the previous trading day, before settling in for the closing price of $0.25. Over the past 52 weeks, XFOR has traded in a range of $0.24-$1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.00%. While this was happening, its average annual earnings per share was recorded -143.86%. With a float of $115.02 million, this company’s outstanding shares have now reached $170.95 million.
Let’s determine the extent of company efficiency that accounts for 143 employees. In terms of profitability, gross margin is 66.41%, operating margin of -1423.58%, and the pretax margin is -1452.48%.
X4 Pharmaceuticals Inc (XFOR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of X4 Pharmaceuticals Inc is 33.77%, while institutional ownership is 30.39%. The most recent insider transaction that took place on May 17 ’24, was worth 14,654. In this transaction Chief Commercial Officer of this company bought 21,646 shares at a rate of $0.68, taking the stock ownership to the 115,769 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Chief Commercial Officer bought 13,404 for $0.34, making the entire transaction worth $4,598. This insider now owns 129,173 shares in total.
X4 Pharmaceuticals Inc (XFOR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -143.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.26% during the next five years compared to 47.41% growth over the previous five years of trading.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
Take a look at X4 Pharmaceuticals Inc’s (XFOR) current performance indicators. Last quarter, stock had a quick ratio of 3.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.19, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.35 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Looking closely at X4 Pharmaceuticals Inc (NASDAQ: XFOR), its last 5-days average volume was 2.34 million, which is a drop from its year-to-date volume of 3.59 million. As of the previous 9 days, the stock’s Stochastic %D was 16.57%. Additionally, its Average True Range was 0.04.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 1.62%, which indicates a significant decrease from 8.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 94.42% in the past 14 days, which was lower than the 202.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4292, while its 200-day Moving Average is $0.5870. However, in the short run, X4 Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2491. Second resistance stands at $0.2617. The third major resistance level sits at $0.2735. If the price goes on to break the first support level at $0.2247, it is likely to go to the next support level at $0.2129. Now, if the price goes above the second support level, the third support stands at $0.2003.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
The company with the Market Capitalisation of 41.05 million has total of 173,662K Shares Outstanding. Its annual sales at the moment are 2,557 K in contrast with the sum of -101,170 K annual income. Company’s last quarter sales were recorded 560 K and last quarter income was -36,700 K.
